Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

DIC to acquire BASF’s worldwide pigments business for $1.3 billion

BASF has announced that DIC Corp. (Tokyo, Japan) will acquire BASF’s worldwide pigments business. The cost of the transaction is €1.15 billion ($1.27 billion) on a debt-free basis.

August 29th, 2019|News|

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain […]

August 26th, 2019|News|

Australia’s Argosy Minerals inks lithium supply deal with Mitsubishi Corp RtM

Lithium miner Argosy Minerals Ltd said on Friday it has signed a preliminary agreement with a unit of Japan’s Mitsubishi Corp for the supply of lithium carbonate product.

August 23rd, 2019|News|

AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New […]

August 23rd, 2019|News|

Chlamydia Vaccine Could Become Reality After Successful Clinical Trial

A vaccine to protect against chlamydia is now a step closer to becoming reality after a pioneering clinical trial has found the treatment to be safe.

August 13th, 2019|News|

Teijin Completes Acquisition of Renegade

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.

August 2nd, 2019|News|

FDA grants Opdivo combo Breakthrough Designation for melanoma

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.

August 2nd, 2019|News|

Shares of Taco Bell owner Yum Brands jump as earnings top estimates

Yum Brands reported second-quarter earnings Thursday that beat Wall Street’s expectations, sending its shares up more than 6%.

August 1st, 2019|News|

Mississippi Lime Completes Acquisition of Southern Lime, Begins Integration of the Calera, Alabama based Business

a leading global supplier of high-calcium lime products and a portfolio company of HBM Holdings, today announced it has completed its acquisition of the Calera, Alabama lime business of Covia (NYSE: CVIA), operating historically as Southern Lime.

August 1st, 2019|News|

Pfizer completes acquisition of Therachon

Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46.

July 5th, 2019|News|